Sfbc (NASDAQ:SFCC)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Sfbc Charts. Click Here for more Sfbc Charts.](/p.php?pid=staticchart&s=N%5ESFCC&p=8&t=15)
Celebrating the 10th Anniversary of the Company, Representatives of
PharmaNet Continue Their Long History of Support for DIA and
Its Membership
Scientists and clinicians representing PharmaNet (a division of
SFBC International) (NASDAQ: SFCC) are addressing many of the
challenges facing the biopharmaceutical research and development
industry at several sessions scheduled to take place at the upcoming
Drug Information Association (DIA) annual meeting in Philadelphia,
Pennsylvania (June 18 - 22, 2006).
"Many of our PharmaNet employees have been involved with the DIA
throughout their careers. In each of our past ten years I have been
especially proud of the number and quality of the presentations given
by our staff at the annual conference," said Jeffrey P. McMullen,
president and chief executive officer, PharmaNet. "Covering topics
including clinical research methodologies, patient recruitment and
retention, enhancing product value, regulatory strategies, training
and strategic clinical trial development, some of our most talented
individuals will be sharing their perspectives with participants at
the DIA meeting. We are honored to have these opportunities. As well,
we are very pleased to continue our long heritage of support for the
DIA meeting."
Among the PharmaNet professionals scheduled to present are:
-- Peggy Schrammel, executive director, late phase development -
Ms. Schrammel is scheduled to chair a session entitled,
"Demonstrating Product Value: Three Unique Perspectives" and
is a speaker of a session entitled, "Strategies for
Outsourcing and Managing Late Phase Trials Using Naive Sites."
She has designed and managed the implementation of late-phase
programs to demonstrate product value for numerous clients. At
PharmaNet, Ms. Schrammel ensures that Late Phase Development
Division programs adhere to the highest standards of
scientific integrity and regulatory compliance while meeting
marketing objectives.
-- Duu-Gong Wu, PhD, executive director, PharmaNet consulting
division - Dr. Wu is a biochemist and molecular biologist
whose professional experience includes senior-level positions
at the Food and Drug Administration Division of New Drug
Chemistry II, with the Center for Drug Evaluation and
Research. Dr. Wu is scheduled to speak in a session entitled,
"Regulatory Considerations on the Development of Botanical
Drug Products in the U.S."
-- Bryce Bartruff, RN, MBA, PhD, manager, clinical research - Mr.
Bartruff has more than 13 years of relevant clinical
experience, including positions as staff nurse, clinical
research associate, senior clinical research scientist and
now, manager of clinical research. At PharmaNet, Mr. Bartruff
has oversight of the Infectious Disease Division's efforts
regarding subject recruitment and retention. He is scheduled
to chair a session entitled, "Reaching Subject Recruitment and
Retention Goals."
-- Michael E. Laird, senior vice president, worldwide business
development - Mr. Laird has more than 20 years of
pharmaceutical and contract research industry experience and
has held senior-level positions at Smith, Kline & French;
Marion Merrell Dow; Proctor & Gamble Pharmaceuticals; and
Kendle. As head of PharmaNet's global business development,
Mr. Laird has daily involvement in leveraging professional
resources as a differentiator among contract research
organizations and is scheduled to chair a session entitled,
"Intellectual Human Capital in Contract Research: Is the
Market There?"
-- Hani Zaki, MPH, MBA, vice president, business development -
Mr. Zaki is scheduled to chair a session entitled, "Strategies
for Outsourcing and Managing Late Phase Trials Using Naive
Sites." Mr. Zaki has worked in both clinical research and
pharmaceutical marketing since 1982, including 11 years of
clinical research in oncology, infectious diseases, allergy
and pulmonology, and CNS. His experience includes service with
Schering-Plough, Bristol-Myers (now BMS), and Rhone-Poulenc
Rorer (now Sanofi-Aventis). Mr. Zaki headed the U.S.
anti-infective clinical operations group for RPR, with
responsibilities for program implementation and resource
allocation.
-- Janet Zimmerman, MSN, senior director, training services - Ms.
Zimmerman has facilitated more than 200 workshops and courses
for clinical research personnel. During a healthcare career
spanning more than 25 years, she has held positions as a
research nurse; clinical research associate (CRA); trainer and
course developer; as well as CRA training manager and is
scheduled to speak at two different DIA sessions including,
"GCP Training Around the Globe: Similarities and Differences
and Using ADDIE to Strategically Analyze and Evaluate Your
Training Program." She is also scheduled to co-present at a
session entitled, "Online Learning: Managing the
Implementation Process" with PharmaNet colleague Robert
Morrison, RN, manager, training services. Mr. Morrison has
more than 26 years of clinical experience, including the last
7 years in contract research. His previous titles have
included therapeutic research associate in oncology and
cardiology, senior clinical research associate, and project
manager.
-- Jim Downhower, MSE, senior director, IT development - Mr.
Downhower has more than 15 years of experience with computer
systems, including 9 years in clinical-development information
technology (IT), and Kim Sanford, director, clinical data
management with more than 15 years of clinical experience,
including positions as CRF data scientist, senior clinical
data analyst, and several positions of increasing
responsibility in clinical data management, are scheduled to
co-present at a session entitled, "Hybrid Data Capture
Strategies."
About PharmaNet/SFBC International, Inc.
PharmaNet is the late stage division of SFBC International, Inc.
As an international drug development services company, SFBC offers a
comprehensive range of clinical development, clinical and
bioanalytical laboratory, and consulting services to the branded
pharmaceutical, biotechnology, generic drug and medical device
industries. The Company has more than 30 offices, facilities and
laboratories with more than 2,000 employees strategically located
throughout the world. PharmaNet represents over half of the Company.
PharmaNet is dedicated to providing the highest level of client
satisfaction and industry-leading expertise to the pharmaceutical,
biotechnology, medical device, and combined-product industries.
Founded in 1996, PharmaNet today continues to deliver a positive
outsourcing experience through its founding principles. For more
information, visit www.sfbci.com and www.pharmanet.com.
Forward-Looking Statements
Certain statements made in this press release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the "Act"). Additionally words such as "seek,"
"intend," "believe," "plan," "estimate," "expect," "anticipate" and
other similar expressions are forward-looking statements within the
meaning of the Act. Some or all of the results anticipated by these
forward-looking statements may not occur. Factors that could cause or
contribute to such differences include, but are not limited to, our
ability to leverage the strong reputation of PharmaNet, whether
adverse publicity relating to SFBC's Miami operations causes clients
to select competitors, not only for early stage branded clinical
trials but also for other aspects of SFBC's business; SFBC's ability
to resolve open issues relating to its Miami property including
whether it can successfully appeal and/or enjoin the Miami-Dade County
Unsafe Structures Board ruling and any related fines or expenses if we
are unsuccessful, the associated costs and expenses with discontinuing
the Company's operations in Miami and Ft. Myers, whether a building
permit will be issued, whether SFBC will prevail in the pending land
lease litigation; continued adverse publicity related to actions of
the United States Senate Finance Committee; developments with respect
to the SEC's inquiry and securities class action lawsuits and
derivative lawsuits; SFBC's assessment of its current FDA inspections;
SFBC's ability to successfully achieve and manage the technical
requirements of specialized clinical trial services, while complying
with applicable rules and regulations; regulatory changes; changes
affecting the clinical research industry; a reduction of outsourcing
by pharmaceutical and biotechnology companies; SFBC's ability to
compete internationally in attracting clients in order to develop
additional business; cancellation of contracts; SFBC's ability to
retain and recruit new employees; SFBC's clients' ability to provide
the drugs and medical devices used in its clinical trials; SFBC's
future stock price; SFBC's financial guidance; and the national and
international economic climate as it affects drug development
operations. Further information can be found in SFBC's risk factors
contained in its Form 10-K filed with the SEC in 2006 and other
filings with the Securities and Exchange Commission.